Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Bio-Rad Laboratories, Inc.NYSE: BIO
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income dips below year-ago levels
Q2 FY2026 operating income of $72.6M fell 5.8% year over year, behind the +5.1% change in trailing-twelve-month operating income. Sequentially, it rose 112.9% from the prior quarter. Over 3 fiscal years it compounded at -17.6% a year.
Context
- Operating income amounted to 10.5% of revenue in FY2025, unchanged from a year earlier.
- Operating income increased in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 2 analysts of $401.29M (+48.4%) for the fiscal year ending Dec 2026, a step up from the +0.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $72.6M+112.9% QoQ
- Last fiscal yearDec 2025
- $270.5M+0.6% YoY
- LTMJun 2026
- $235M+5.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- 270.5M USD
- Year-over-year change
- +0.6%
- 4-year CAGR
- -14.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 270.5M | +0.6% |
| FY2024 | 2024-12-31 | 269M | -20.4% |
| FY2023 | 2023-12-31 | 337.8M | -30.0% |
| FY2022 | 2022-12-31 | 482.62M | -3.5% |
| FY2021 | 2021-12-31 | 500.34M | — |
Operating Income vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's LTM Jun 2026 operating income of $235M is the 5th highest of the 11 companies compared; the peer median is $111.29M.
- Its year-over-year change of +5.1% is the 7th highest of 11, against a peer median of +19.6%.
- Operating income amounts to 9.1% of revenue for BIO, versus a peer median of 20.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.52B | +5.1% | -1.7% | 18.0% | |
| LTM Sep 2026 | $5.22B | -2.8% | -12.0% | 20.4% | |
| LTM Jul 2026 | $358.85M | -9.8% | -23.0% | 12.3% | |
| LTM Sep 2026 | $240.84M | +119.1% | -5.5% | 19.6% | |
| LTM Jun 2026 | $235M | +5.1% | -17.6% | 9.1% | |
| LTM Jun 2026 | $126.5M | -31.2% | -18.3% | 3.6% | |
| LTM Jun 2026 | $96.09M | +129.8% | — | 46.0% | |
| LTM Jun 2026 | $65.3M | +373.7% | -35.8% | 8.3% | |
| LTM Mar 2026 | -$78.51M | +34.0% | — | 91.0% | |
| LTM Mar 2026 | -$162.78M | +80.2% | — | 101.7% | |
| LTM Sep 2026 | -$172.34M | -2543.7% | — | 27.7% | |
| Peer median (excluding BIO) | $111.29M | +19.6% | -15.1% | 20.0% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B |
| Cost of Revenue | 1.28B | 1.23B | 1.24B | 1.19B | 1.24B |
| Gross Profit | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B |
| Gross Margin | 56.1% | 55.9% | 53.4% | 53.7% | 52.0% |
| Research & Development | 260.64M | 256.89M | 247.43M | 295.9M | 256.9M |
| Selling, General & Admin | 877.12M | 827.83M | 841.7M | 814M | 819.9M |
| Operating Expenses | 1.14B | 1.08B | 1.09B | 1.11B | 1.08B |
| Depreciation & Amortization | 137.6M | 137.3M | 145.9M | 151.6M | 165.4M |
| EBITDA | 5.59B | (4.53B) | (654.8M) | (2.14B) | 1.21B |
| EBITDA Margin | 191.2% | -161.6% | -24.5% | -83.5% | 46.8% |
| Operating Income | 500.34M | 482.62M | 337.8M | 269M | 270.5M |
| Operating Margin | 17.1% | 17.2% | 12.6% | 10.5% | 10.5% |
| Interest Income | 18.9M | 58M | 100.9M | 82M | 95.5M |
| Interest Expense | 1.55M | 38.11M | 49.44M | 48.9M | 49M |
| Other Income / Expenses | 4.95B | (5.19B) | (1.19B) | (2.61B) | 725M |
| Income Before Tax | 5.45B | (4.7B) | (850.1M) | (2.34B) | 995.5M |
| Pre-Tax Margin | 186.4% | -167.9% | -31.8% | -91.3% | 38.5% |
| Income Tax Expense | 1.19B | (1.08B) | (212.78M) | (498.3M) | 235.6M |
| Net Income | 4.25B | (3.63B) | (637.32M) | (1.84B) | 759.9M |
| Net Margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (Basic) | 142.61 | (121.79) | (21.82) | (65.36) | 27.87 |
| EPS (Diluted) | 140.83 | (121.79) | (21.82) | (65.36) | 27.87 |
| Weighted Avg Shares | 29.83M | 29.79M | 29.21M | 28.21M | 27.26M |
| Weighted Avg Shares (Diluted) | 30.21M | 29.79M | 29.21M | 28.21M | 27.28M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.